Omeros

Omeros responds to Statnews.com story

Tuesday, August 29, 2017

Omeros stated that it continues to pursue legal action to hold responsible those behind a series of defamatory reports about the company posted online under the pseudonym “Art Doyle,” an entity or group that self-identifies as having a short position in Omeros’ stock. Because of its ongoing legal action, including a number of steps aimed at unmasking the identity of the individual(s) responsible, Omeros elected not to respond to queries from a writer for statnews.com who evidently had early access to and commented through Twitter on the initial “Art Doyle” false report before it was broadly made public.

[Read More]

Omeros’s phase II OMS721 trial completes dosing, extended access for compassionate use

Thursday, February 26, 2015

Omeros has completed dosing of the low-dose cohort of patients in its ongoing phase II clinical trial evaluating the efficacy and safety of OMS721, the lead human monoclonal antibody for its mannan-binding lectin-associated serine protease-2 (MASP-2) program, in treating thrombotic microangiopathies (TMAs). TMAs are a family of rare, debilitating and life-threatening disorders characterized by excessive thrombi (clots) in the microcirculation of the body’s organs, most commonly the kidney and brain.

[Read More]

Omeros reports positive results from OMS824 phase IIa clinical trial

Friday, January 31, 2014

Omeros has announced positive results from a phase IIa clinical trial of OMS824, the company’s phosphodiesterase 10 (PDE10) inhibitor, in which the drug was well-tolerated and demonstrated comparable systemic pharmacokinetics when administered alone and concomitantly with approved antipsychotic agents in patients with schizophrenia. OMS824 selectively inhibits PDE10, an enzyme expressed in areas of the brain linked to a wide range of diseases that affect cognition, including schizophrenia and Huntington’s disease.

[Read More]

Omeros adds two new vice presidents to management team

Friday, October 19, 2012

Omeros, a Seattle, Wash.-based clinical-stage biopharmaceutical company targeting inflammation, coagulopathies and disorders of the central nervous system, has appointed two new vice presidents: Cathy Melfi, Ph.D. as vice president, regulatory affairs and quality systems, and Albert Yu, M.D., as vice president, clinical development.

[Read More]

Omeros unlocks 20% of Class A orphans

Wednesday, November 30, 2011

Omeros has reported that with its identification of compounds that interact
selectively with each of four additional orphan G protein-coupled receptors (GPCRs) – GPR19, GPR20, GPR31 and GPR141 – it has now unlocked over 20% of the 77 Class A orphans. GPCRs represent the premier family of drug targets, with more than 30% of currently marketed drugs targeting only 46 GPCRs. There are approximately 120 orphan GPCRs, and Omeros is initially targeting Class A orphan GPCRs.

[Read More]